Article ; Online: Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes.
The Journal of clinical investigation
2020 Volume 130, Issue 10, Page(s) 5223–5234
Abstract: Dengue virus (DENV) infection requires cholesterol as a proviral factor, although statin treatment did not show antiviral efficacy in patients with dengue. Here, we show that DENV infection manipulated cholesterol metabolism in cells residing in low- ... ...
Abstract | Dengue virus (DENV) infection requires cholesterol as a proviral factor, although statin treatment did not show antiviral efficacy in patients with dengue. Here, we show that DENV infection manipulated cholesterol metabolism in cells residing in low-oxygen microenvironments (hypoxia) such as in the liver, spleen, and lymph nodes. DENV infection induced expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces low-density lipoprotein receptor (LDLR) recycling and hence cholesterol uptake. We found that, whereas LDLR uptake would have distributed cholesterol throughout the various cell compartments, de novo cholesterol synthesis enriched this lipid in the endoplasmic reticulum (ER). With cholesterol enrichment in the ER, ER-resident STING and type I IFN (IFN) activation was repressed during DENV infection. Our in vitro findings were further supported by the detection of elevated plasma PCSK9 levels in patients with dengue with high viremia and increased severity of plasma leakage. Our findings therefore suggest that PCSK9 plays a hitherto unrecognized role in dengue pathogenesis and that PCSK9 inhibitors could be a suitable host-directed treatment for patients with dengue. |
---|---|
MeSH term(s) | Adolescent ; Adult ; Antiviral Agents/pharmacology ; Cell Hypoxia ; Cell Line ; Child ; Cholesterol/metabolism ; Dengue/drug therapy ; Dengue/etiology ; Dengue/metabolism ; Dengue Virus/pathogenicity ; Drug Resistance, Viral ; Female ; Hepatocytes/metabolism ; Hepatocytes/virology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Male ; Myeloid Cells/metabolism ; Myeloid Cells/virology ; Proprotein Convertase 9/blood ; Proprotein Convertase 9/metabolism ; Receptors, LDL/metabolism ; Young Adult |
Chemical Substances | Antiviral Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; LDLR protein, human ; Receptors, LDL ; Cholesterol (97C5T2UQ7J) ; PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) |
Language | English |
Publishing date | 2020-08-24 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 3067-3 |
ISSN | 1558-8238 ; 0021-9738 |
ISSN (online) | 1558-8238 |
ISSN | 0021-9738 |
DOI | 10.1172/JCI137536 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ua VI Zs.184: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.